Chen Shen

Dr. Chen Shen

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

5 January 2024 in Applied Biochemistry and Biotechnology
Verified
Journal Article
Closed access
PDF file
CSChen Shen
Chen Shen
YWYongfa Wang
Yongfa Wang

25 February 2025 in Plant Physiology and Biochemistry
Verified
Journal Article
Closed access
YZYawen Zhao
Yawen Zhao
ZWZhenzhen Wu
Zhenzhen Wu
JLJiayao Li
Jiayao Li
YQYaoxing Qi
Yaoxing Qi
XZXiaoxiao Zhang
Xiaoxiao Zhang
CSChen Shen
Chen Shen

2 May 2025 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
JLJiayao Li
Jiayao Li
YZYawen Zhao
Yawen Zhao
CSChen Shen
Chen Shen

19 September 2018 in Molecules
Verified
Journal Article
Open access
PDF file
LLLi Li
Li Li
CSChen Shen
Chen Shen
YHYa-Xuan Huang
Ya-Xuan Huang
YLYa-Nan Li
Ya-Nan Li
XLXiu-Feng Liu
Xiu-Feng Liu
JLJi-Hua Liu
Ji-Hua Liu
The interaction between proprotein convertase subtilisin/kexin type 9 (PCSK9) and the low-density lipoprotein receptor (LDLR) is a promising target for the treatment of hyperc-holesterolemia. In this study, a new method based on competitive affinity and tag detection was developed, which aimed to evaluate potent natural inhibitors preventing the interaction of PCSK9/LDLR directly. Herein, natural compounds with efficacy in the treatment of hypercholesterolemia were chosen to investigate their inhibitory activities on the PCSK9/LDLR interaction. Two of them, polydatin (1) and tetrahydroxydiphenylethylene-2-O-glucoside (2), were identified as potential inhibitors for the PCSK9/LDLR interaction and were proven to prevent PCSK9-mediated LDLR degradation in HepG2 cells. The results suggested that this strategy could be applied for evaluating potential bioactive compounds inhibiting the interaction of PCSK9/LDLR and this strategy could accelerate the discovery of new drug candidates for the treatment of PCSK9-mediated hypercholesterolemia.

28 September 2023 in Biotechnology and Bioengineering
Verified
Journal Article
Closed access
YWYongfa Wang
Yongfa Wang
HPHao Pan
Hao Pan
FWFuhao Wang
Fuhao Wang
CSChen Shen
Chen Shen